CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Xenon Pharmaceuticals Inc. (XENE) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Xenon Pharmaceuticals Inc. (XENE)

Pharmaceutical Preparations · market cap $3.6B · as of 2026-10-27

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2026-11-09 (est.)
Earnings
Pipeline
5
programs
Upcoming events
5
next 90d+
Dossier
Ready
cached
Xenon Pharmaceuticals (XENE) is a 316-employee clinical-stage biopharma with a ~$3.46B market cap (~$35.77/share). Our data lists azetukalner in Phase 3 for Major Depressive Disorder as the lead asset, with a Phase 3 PGTCS program, an estimated epilepsy PDUFA date, and three Phase 2 programs (dental pain, postherpetic neuralgia, acne vulgaris). Our calendar shows a dense run of estimated catalysts between Jan and May 2027, so the setup is event-heavy.
The catalyst path
  • 2026-11-09 (est.)Earningsimp 5/10
  • 2027-01-15 (est.)Phase 3 · Azetukalnerimp 9/10
  • 2027-03-04 (est.)PDUFA · Azetukalnerimp 8/10
  • 2027-04-15 (est.)Phase 3 · XEN1101imp 9/10
  • 2027-05-15 (est.)Phase 3 · Azetukalnerimp 9/10
Pipeline
AssetPhaseIndication
XEN1101Phase 3Primary Generalized Tonic-Clonic Seizures
AzetukalnerPhase 3Major Depressive Disorder
XPF-005Phase 2Acne Vulgaris
XPF-001Phase 2Dental Pain
XPF-002Phase 2Postherpetic Neuralgia
Price & technical context
3-month
-40.5%
6-month
-32.7%
12-month
-3.6%
52-wk range
$33.49–$70.96
vs 50-day MA
-13.4%
vs 200-day MA
-28.0%
Realized vol
64.4%
Max drawdown
-52.8%

Daily closes through 2026-11-05. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for XENE (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.